“…Involvement of GluN2A-containing NMDA (GluN2A-NMDA) receptor in the development of LTP is supported by the findings that pharmacological inhibition of GluN2A by NVP-AAM077 blocks the induction of LTP in multiple brain regions including the hippocampus (Bartlett et al, 2007;Fox et al, 2006;Jin and Feig, 2010;Li et al, 2007;Liu et al, 2004;Volianskis et al, 2013), the cortex (Massey et al, 2004) as well as the amygdala (Dalton et al, 2012;Muller et al, 2009) and the nucleus accumbens (Schotanus and Chergui, 2008). Deletion of GluN2A subunit in mice results in a impaired induction of postsynaptic LTP in the dentate gyrus (Kannangara et al, 2014) and the visual cortex (Philpot et al, 2007), and at the mossy fiber to granule cell synapse in the cerebellum (Andreescu et al, 2011). On the other hand, the GluN2A-NMDA receptor is required for the glycine-evoked membrane insertion of new AMPA (a-amino-3-hydroxy-5-methy-4-isoxazole propionate) receptors (AMPARs) as well as the induction of LTP in the rat visual cortex (Li and Wang, 2013), and synaptic GluN2A-NMDA receptors are more likely to mediate the transiently increased phosphorylation of AMPAR GluA1 subunit at serine site S831 by bath application of NMDA to hippocampal slices from rats (Ai et al, 2011).…”